Company intelligence / Profile preview
Angiex
Cambridge, Massachusetts, United Statesangiex.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Angiex has initiated a first-in-human, open-label Phase I trial of its lead candidate AGX101, a novel ND‑ADC targeting TM4SF1. The trial aims to assess safety, pharmacokinetics, and preliminary anti-tumor activity in patients with solid tumors. Preclinical data demonstrated selective killing of both tumor cells and tumor endothelial cells with no known resistance mechanisms. The company’s approach may offer new hope for aggressive cancers resistant to existing therapies[6][8][10].
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Antibody-drug conjugates (ADCs)Nuclear-delivered ADCs (ND-ADCs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Abzena (CDMO partner for bioconjugation and cGMP manufacturing of AGX101 clinical material)[6]Outlicensing plans to pharma/biotech partners for vascular indications[7]
Beyond the preview
Go deeper on Angiex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angiex.